And they are being trial on different cancer, CF33 has been expand to CCA, Azer-Cel is targeting DLBCL and OnCARlytic will be for solid cancer which can be effectively express with CD19 using CF33 and killed with CAR-T (Azer-Cel when approved). So why didn't you question whether a patient has to pay for all 3 treatments??
IMU Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)